New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Blueprint Medicines Corporation
BPMC
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

5B

Biotechnology

Next Earning date - 30 Oct 2024

5B

Biotechnology

Next Earning date - 30 Oct 2024

82.47USD
Shape-0.62 ( -0.75%)
favorite-chart

Relative Strenght

91
favorite-chart

Volume Buzz

-37%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

32%

Quote Panel

Shape
Updated October 27, 2024
1W -3.67 % 1M -10.84 % 3M -25.26 % 1Y 51.77 %

Key Metrics

Shape
  • Market Cap

    5.22B


  • Shares Outstanding

    63.35M


  • Share in Float

    62.20M


  • Dividende

    0


  • Earning Date

    30 Oct 2024


  • Price Target

    82.47


  • Average Volume

    654164


  • Beta

    0.578


  • Range

    53.13-121.9


  • Industry

    Biotechnology


  • Website

    https://www.blueprintmedicines.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

14.40x

P/S Ratio

16.19x

P/B Ratio

2.1

Debt/Equity

-56.6%

Net Margin

$-3.4

EPS

How BPMC compares to sector?

P/E Ratio

Relative Strength

Shape

BPMC

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$697M

Shape404%

2025-Revenue

$1.37

Shape-71%

2025-EPS

$503M

Shape-1176%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

UBS

initialise

Previous: Not converted

2024-10-24

Now: Neutral

Stephens

initialise

Previous: Not converted

2024-05-13

Now: Overweight

Leerink Partners

upgrade

Previous: Not converted

2024-05-06

Now: Market Perform

Wells Fargo

upgrade

Previous: Not converted

2023-07-31

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-2.23
vs -2.00

Q4.22

arrow
arrow

N/A

-2.65
vs -0.99

Q1.23

arrow
arrow

N/A

-2.15
vs -1.79

Q2.23

arrow
arrow

N/A

-2.19
vs -2.68

Q3.23

arrow
arrow

N/A

-2.20
vs -2.23

Q4.23

arrow
arrow

N/A

-1.82
vs -2.65

Q1.24

arrow
arrow

N/A

-1.32
vs -2.15

Q2.24

arrow
arrow

N/A

-0.80
vs -2.19

Q3.24

arrow
arrow

N/A

-0.96
vs -2.20

Q4.24

arrow
arrow

N/A

-0.84
vs -1.82

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+173%

66M  vs 24.2M

Q4.22

arrow
arrow

-64%

38.8M  vs 107M

Q1.23

arrow
arrow

+1%

63.3M  vs 62.7M

Q2.23

arrow
arrow

+58%

57.6M  vs 36.5M

Q3.23

arrow
arrow

-14%

56.6M  vs 66M

Q4.23

arrow
arrow

+86%

72M  vs 38.8M

Q1.24

arrow
arrow

+52%

96.1M  vs 63.3M

Q2.24

arrow
arrow

+140%

138.2M  vs 57.6M

Q3.24

arrow
arrow

+126%

127.6M  vs 56.6M

Q4.24

arrow
arrow

+91%

137.4M  vs 72M

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-21%

-0.21
vs -0.21

Q4.22

arrow
arrow

-31%

-0.31
vs -0.21

Q1.23

arrow
arrow

-31%

-0.31
vs -0.31

Q2.23

arrow
arrow

-43%

-0.43
vs -0.31

Q3.23

arrow
arrow

-66%

-0.66
vs -0.43

Q4.23

arrow
arrow

-85%

-0.85
vs -0.66

Q1.24

arrow
arrow

+29%

0.29
vs -0.85

Q2.24

arrow
arrow

-16%

-0.16
vs 0.29

Institutionnal OwnershipShape

status-upQoQ

Q3.22

arrow
arrow

236

236
vs 239

-1%

Q4.22

arrow
arrow

232

232
vs 236

-2%

Q1.23

arrow
arrow

228

228
vs 232

-2%

Q2.23

arrow
arrow

234

234
vs 228

3%

Q3.23

arrow
arrow

234

234
vs 234

NA

Q4.23

arrow
arrow

280

280
vs 234

20%

Q1.24

arrow
arrow

307

307
vs 280

10%

Q2.24

arrow
arrow

329

329
vs 307

7%

Earnings Growth

Latest News